Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis

References

• ChiangYPWangFJavittJCOffice visits to ophthalmologists and other physicians for eye care among the US population, 1990Public Health Rep199511021471537630990
   PubMed Web of Science ®Google Scholar
• SoukiasianSHBaumJBacterial conjunctivitisKrachmerJHMannisMJHollandEJCornea3rd edPhiladelphia, PAElsevier Mosby2010
   Google Scholar
• PerkinsREKundsinRBPrattMVAbrahamsenILeibowitzHMBacteriology of normal and infected conjunctivaJ Clin Microbiol1975121471491176598
   PubMed Web of Science ®Google Scholar
• BrookIPettitTHMartinWJFinegoldSMAnaerobic and aerobic bacteriology of acute conjunctivitisAnn Ophthalmol1979113389393313179
   PubMedGoogle Scholar
• EverettSLKowalskiRPKarenchakLMLandsittelDDayRGordonYJAn in vitro comparison of the susceptibilities of bacterial isolates from patients with conjunctivitis and blepharitis to newer and established topical antibioticsCornea19951443823877671609
   PubMed Web of Science ®Google Scholar
• CavuotoKZutshiDKarpCLMillerDFeuerWUpdate on bacterial conjunctivitis in South FloridaOphthalmology20081151515617572497
   PubMed Web of Science ®Google Scholar
• GigliottiFWilliamsWTHaydenFGEtiology of acute conjunctivitis in childrenJ Pediatr19819845315366970802
   PubMed Web of Science ®Google Scholar
• BorerALivshiz-RivenIGolanAHospital-acquired conjunctivitis in a neonatal intensive care unit: Bacterial etiology and susceptibility patternsAm J Infect Control201038865065220392539
   PubMed Web of Science ®Google Scholar
• AdebayoAParikhJGMcCormickSAShifting trends in in vitro susceptibilities for common bacterial conjunctival isolates in the last decade at the New York Eye and Ear InfirmaryArch Clin Exp Ophthalmol20112491111119
   PubMed Web of Science ®Google Scholar
• American Academy of OphthalmologyPreferred practice patterns: Conjunctivitis2008 Available from: http://one.aao.org/CE/PracticeGuidelines/PPP.aspx. Accessed December 28, 2010.
   Google Scholar
• PatelPBDiazMCBennettJEAttiaMWClinical features of bacterial conjunctivitis in childrenAcad Emerg Med20071411517119185
   PubMed Web of Science ®Google Scholar
• BuznachNDaganRGreenbergDClinical and bacterial characteristics of acute bacterial conjunctivitis in children in the antibiotic resistance eraPediatr Infect Dis J200524982382816148850
   PubMed Web of Science ®Google Scholar
• SmolinGOkumotoMStaphylococcal blepharitisArch Ophthalmol1977955812816324453
   PubMedGoogle Scholar
• Van BijsterveldOPThe incidence of Moraxella on mucous membranes and the skinAm J Ophthalmol197274172765036450
   PubMed Web of Science ®Google Scholar
• AungTChanTKNosocomial Klebsiella pneumoniae conjunctivitis resulting in infectious keratitis and bilateral corneal perforationCornea19981755585619756452
   PubMed Web of Science ®Google Scholar
• KingSDeviSPMindorffCPatrickMLGoldRFord-JonesELNosocomial Pseudomonas aeruginosa conjunctivitis in a pediatric hospitalInfect Control Hosp Epidemiol19889277803125244
   PubMed Web of Science ®Google Scholar
• SheikhAHurwitzBTopical antibiotics for acute bacterial conjunctivitis: Cochrane systematic review and meta-analysis updateBr J Gen Pract20055552196296416378567
   PubMed Web of Science ®Google Scholar
• RosePWZieblandSHarndenAMayon-WhiteRMantDOxford Childhood Infection Study Group (OXCIS). Why do general practitioners prescribe antibiotics for acute infective conjunctivitis in children? Qualitative interview with GPs and a questionnaire survey of parents and teacherFam Pract200623222623216339771
   PubMed Web of Science ®Google Scholar
• BaumJBarzaMThe evolution of antibiotic therapy for bacterial conjunctivitis and keratitis: 1970–2000Cornea200019565967211009318
   PubMed Web of Science ®Google Scholar
• RosePManagement strategies for acute infective conjunctivitis in primary care: A systematic reviewExpert Opin Pharmacother20078121903192117696792
   PubMed Web of Science ®Google Scholar
• GibsonJRTrimethoprim-polymyxin B ophthalmic solution in the treatment of presumptive bacterial conjunctivitis – a multicentre trial of its efficacy versus neomycin-polymyxin B-gramicidin and chloramphenicol ophthalmic solutionsJ Antimicrob Chemother19831132172216188739
   PubMed Web of Science ®Google Scholar
• EverittHLittlePHow do GPs diagnose and manage acute infective conjunctivitis? A GP surveyFam Pract200219665866012429670
   PubMed Web of Science ®Google Scholar
• EverittHALittlePSSmithPWA randomised controlled trial of management strategies for acute infective conjunctivitis in general practiceBMJ2006333756332116847013
   PubMed Web of Science ®Google Scholar
• KowalskiRPKarenchakLMRomanowskiMSInfectious disease: Changing antibiotic susceptibilityOphthalmol Clin North Am20031611912683244
   PubMedGoogle Scholar
• AsbellPAColbyKADengSOcular TRUST: Nationwide antimicrobial susceptibility patterns in ocular isolatesAm J Ophthalmol2008145695195818374299
   PubMed Web of Science ®Google Scholar
• MahFSFourth-generation fluoroquinolones: New topical agents in the war on ocular bacterial infectionsCurr Opin Ophthalmol200415431632015232471
   PubMedGoogle Scholar
• HooperDCWolfsonJSFluoroquinolone antimicrobial agentsN Engl J Med199132463843941987461
   PubMed Web of Science ®Google Scholar
• FishDNNorthDSGatifloxacin, an advanced 8-methoxy fluoroquinolonePharmacotherapy2001211355911191737
   PubMed Web of Science ®Google Scholar
• OlsonRZymar® as an ocular therapeutic agentInt Ophthalmol Clin2006464738417060793
   PubMedGoogle Scholar
• BlondeauJMLaskowskiRBjarnasonJStewartCComparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organismsInt J Antimicrob Agents2000141455010717500
   PubMed Web of Science ®Google Scholar
• MatherRKarenchakLMRomanowskiEGKowalskiRPFourth generation fluoroquinolones: New weapons in the arsenal of ophthalmic antibioticsAm J Ophthalmol2002133446346611931779
   PubMed Web of Science ®Google Scholar
• ScoperSVReview of third-and fourth-generation fluoroquinolones in ophthalmology: In-vitro and in-vivo efficacyAdv Ther2008251097999418836691
   PubMed Web of Science ®Google Scholar
• SandersCCReview of preclinical studies with ofloxacinClin Infect Dis19921425265381554842
   PubMed Web of Science ®Google Scholar
• WisemanLRBalfourJACiprofloxacin. A review of its pharmacological profile and therapeutic use in the elderlyDrugs Aging1994421451738186542
   PubMed Web of Science ®Google Scholar
• KhodurskyABZechiedrichELCozzarelliNRTopoisomerase IV is a target of quinolones in Escherichia coliProc Natl Acad Sci U S A1995922511801118058524852
   PubMed Web of Science ®Google Scholar
• BreinesDMOuabdesselamSNgEYQuinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IVAntimicrob Agents Chemother19974111751798980775
   PubMed Web of Science ®Google Scholar
• PestovaEMillichapJJNoskinGAPetersonLRIntracellular targets of moxifloxacin: A comparison with other fluoroquinolonesJ Antimicrob Chemother200045558359010797078
   PubMed Web of Science ®Google Scholar
• WolfsonJSHooperDCBacterial resistance to quinolones: Mechanisms and clinical importanceRev Infect Dis198911Suppl 5S960S9682549610
   PubMedGoogle Scholar
• BrownWMGatifloxacin Kyorin Pharmaceutical CoCurr Opin Investig Drugs2000113544
   Google Scholar
• Park-WyllieLYJuurlinkDNKoppAOutpatient gatifloxacin therapy and dysglycemia in older adultsN Engl J Med2006354131352136116510739
   PubMed Web of Science ®Google Scholar
• Zymar^® [Package insert]Irvine, CAAllergan Inc2003
   Google Scholar
• Zymaxid™ [Package insert]Irvine, CAAllergan Inc2010
   Google Scholar
• OliveiraADD’AzevedoPAFranciscoWIn vitro activity of fluoroquinolones against ocular bacterial isolates in Sao Paulo, BrazilCornea200726219419817251812
   PubMed Web of Science ®Google Scholar
• KowalskiRPYatesKARomanowskiEGKarenchakLMMahFSGordonYJAn ophthalmologist’s guide to understanding antibiotic susceptibility and minimum inhibitory concentration dataOphthalmology20051121987199116183128
   PubMed Web of Science ®Google Scholar
• KowalskiRPDhaliwalDKKarenchakLMGatifloxacin and moxifloxacin: An in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolatesAm J Ophthalmol2003136350050512967804
   PubMed Web of Science ®Google Scholar
• MillerDReview of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infectionsClin Ophthalmol200821779119668391
   PubMedGoogle Scholar
• BlondeauJMBorsosSHesjeCKAntimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureusJ Chemother200719214615117434822
   PubMed Web of Science ®Google Scholar
• CalleganMCNovosadBDRamadanRTWiskurBMoyerALRate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolonesAdv Ther200926444745419381523
   PubMed Web of Science ®Google Scholar
• HesjeCKBorsosSDBlondeauJMBenzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strainsJ Ocul Pharmacol Ther200925432933419650708
   PubMed Web of Science ®Google Scholar
• BlondeauJMHedlinPBorsosSDThe antimicrobial activity of gatifloxacin (GAT) with or without benzalkonium chloride (BAK) against ocular bacterial pathogensInvest Ophthalmol Vis Sci200546 Abstr 4880
   Web of Science ®Google Scholar
• E BorsosSDBlondeauJMHesjeCKComparative in vitro potency of levofloxacin (Lfx) and gatifloxacin (Gfx) plus benzalkonium chloride (BAK) against gram-positive (GP) pathogens including methicillin-resistant Staphylococcus aureus (MRSA)Invest Ophthalmol Vis Sci200849 Abstr 1980
   Google Scholar
• McDonaldMBlondeauJMEmerging antibiotic resistance in ocular infections and the role of fluoroquinolonesJ Cataract Refract Surg20103691588159820692574
   PubMed Web of Science ®Google Scholar
• RomanowskiEGMahFSKowalskiRPYatesKAGordonYJBenzalkonium chloride enhances the antibacterial efficacy of gatifloxacin in an experimental rabbit model of intrastromal keratitisJ Ocul Pharmacol Ther200824438038418665809
   PubMed Web of Science ®Google Scholar
• HyonJYEserIO’BrienTPKill rates of preserved and preservative-free topical 8-methoxyfluoroquinolones against various strains of StaphylococcusJ Cataract Refract Surg20093591609161319683161
   PubMed Web of Science ®Google Scholar
• CalleganMCNovosadBDRamadanRTWiskurBMoyerALRate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolonesAdv Ther200926444745419381523
   PubMed Web of Science ®Google Scholar
• KowalskiRPKarenchakLMGordonYJComparison of ciprofloxacin and ofloxacin using human corneal susceptibility levelsCornea19981732822879603384
   PubMed Web of Science ®Google Scholar
• RomanowskiEGMahFSYatesKAKowalskiRPGordonYJThe successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar® (gatifloxacin 0.3%) in a NZW rabbit modelAm J Ophthalmol2005139586787715860293
   PubMed Web of Science ®Google Scholar
• KimDHStarkWJO’BrienTPDickJDAqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patientsOphthalmology2005112111992199616183125
   PubMed Web of Science ®Google Scholar
• SolomonRDonnenfeldEDPerryHDPenetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humorOphthalmology2005112346646915745775
   PubMed Web of Science ®Google Scholar
• McCulleyJPCaudleDAronowiczJDShineWEFourth-generation fluoroquinolone penetration into the aqueous humor in humansOphthalmology2006113695595916603244
   PubMed Web of Science ®Google Scholar
• KatzHRMasketSLaneSSAbsorption of topical moxifloxacin ophthalmic solution into human aqueous humorCornea200524895595816227840
   PubMed Web of Science ®Google Scholar
• Ong-ToneLAqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given by different methods before cataract surgeryJ Cataract Refract Surg2007331596217189794
   PubMed Web of Science ®Google Scholar
• SugiokaKFukudaMKomotoSItahashiMYamadaMShimomuraYIntraocular penetration of sequentially instilled topical moxifloxacin, gatifloxacin, and levofloxacinClin Ophthalmol2009355355719898627
   PubMedGoogle Scholar
• AiharaMMiyanagaMMinamiKA comparison of fluoroquinolone penetration into human conjunctival tissueJ Ocul Pharmacol Ther200824658759119049265
   PubMed Web of Science ®Google Scholar
• WagnerRSAbelsonMBShapiroATorkildsenGEvaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissueArch Ophthalmol200512391282128316157821
   PubMedGoogle Scholar
• TorkildsenGProkschJWShapiroALynchSKComstockTLConcentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administrationClin Ophthalmol2010433134120463802
   PubMedGoogle Scholar
• YeeRWTepedinoMBernsteinPJensenHSchiffmanRWhitcupSMA randomized, investigator-masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment BID versus QID for the treatment of acute bacterial conjunctivitis of acute bacterial conjunctivitisCurr Med Res Opin200521342543115811211
   PubMed Web of Science ®Google Scholar